Efmarodocokin alfa

DB16398InvestigationalProtein Based Therapies

Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

Mechanism: Efmarodocokin alfa is a human IL-22Fc IgG4 fusion protein that activates the IL-22 pathway being investigated for inflammatory diseases. Studies show activation of STAT3 in primary human hepatocytes and human colon cell lines.
Curator reviewed
Also known as: HUMAN INTERLEUKIN 22 (1-146), FUSED TO HUMAN IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 4 (CH1(97-98), H(S10>P(158)), CH2(N67>G(227)))-(147-377), DIMER (156-156':159-159')-BISDISULFIDE, PRODUCED IN CHO CELLS, GLYCOFORM ALFA · IL 22-FC · IL-22Fc · INTERLEUKIN 22 (HUMAN (MATURE)) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (SYNTHETIC HUMAN .GAMMA.4-CHAIN FC REGION (81-GLYCINE)), DIMER
Code names: RG-7880 · RO-7021610 · UTTR1147A

Resolves to

Compound

UNIINYZ11835VXCAS1953227-87-6

Targets

Q8N6P7IL22RA1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Efmarodocokin alfa, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account